恶性黑色素瘤化疗研究进展

doi:10.11904/j.issn.1002-3070.2019.02.013

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (2): 167-172.doi: 10.11904/j.issn.1002-3070.2019.02.013

恶性黑色素瘤化疗研究进展

秦岚群¹(综述), 邹征云²(审校)

1.南京医科大学鼓楼临床医学院肿瘤中心(南京 210008);
2.南京大学医学院附属鼓楼医院肿瘤中心

收稿日期:2018-10-11 修回日期:2018-11-28 出版日期:2019-04-20 发布日期:2019-04-25
通讯作者: 邹征云,E-mail:zouzhengyun001@163.com
作者简介:秦岚群,女,(1994-),硕士研究生,从事恶性肿瘤生物免疫治疗相关的研究
基金资助:
1.南京市医学科技发展项目(编号:ZKX15012); 2.中央高校基本科研项目(编号:021414380427); 3.国家自然科学基因(编号:81872484)

Progress in chemotherapy for malignant melanoma

QIN Lanqun¹, ZOU Zhengyun²

1.The Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical School, Nanjing 210008, China;
2.The Comprehensive Cancer Center, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

Received:2018-10-11 Revised:2018-11-28 Online:2019-04-20 Published:2019-04-25

摘要/Abstract

摘要： 恶性黑色素瘤(Malignant melanoma,MM)是一种恶性程度极高的实体肿瘤,它极具侵袭性,预后差。尽管晚期黑色素瘤的治疗已经进入靶向和免疫治疗的时代,但是化疗仍然不可摒弃。恶性黑色素瘤的化疗经历了从单药化疗、两药或三药甚至四药的联合化疗、再到生物化疗这一发展过程。本文综述恶性黑色素瘤化疗研究进展,对主要的化疗方案进行比较,展望化疗未来发展的方向。

关键词: 恶性黑色素瘤, 化疗, 生物化疗, 靶向疗法

Abstract: Malignant melanoma(MM)is a very malignant solid tumor that is highly invasive and has a poor prognosis.Although the treatment of advanced melanoma has entered the era of targeting and immunotherapy,chemotherapy is still not to be abandoned.Chemotherapy for malignant melanoma has undergone a development process from single-drug chemotherapy,combination of two or three or even four drugs,and biochemotherapy.This article reviews the progress of chemotherapy for malignant melanoma,compares the main chemotherapy regimens,and looks forward into the future direction of chemotherapy.

Key words: Malignant melanoma, Chemotherapy, Biochemotherapy, Targeting therapy

中图分类号:

R739.5

秦岚群, 邹征云. 恶性黑色素瘤化疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 167-172.

QIN Lanqun, ZOU Zhengyun. Progress in chemotherapy for malignant melanoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 167-172.

参考文献

1 Eggermont AM,Spatz A,Robert C.Cutaneous melanoma[J].Lancet,2014,383(9919):816-827.
2 Gupta A,Gomes F,Lorigan P.The role for chemotherapy in the modern management of melanoma[J].Melanoma Management,2017,4(2):125-136.
3 Middleton M,Grob J,Aaronson N,et al.Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma[J].J Clin Oncol,2000,18(1):158-166.
4 Avril MF,Aamdal S,Grob JJ,et al.Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:a phase III study[J].J Clin Oncol,2004,22(6):1118-1125.
5 Teimouri F,Nikfar S,Abdollahi M.Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma:a meta-analysis consisting of 1314 patients[J].Melanoma Res,2013,23(5):381-389.
6 Yardley DA.Nab-paclitaxel mechanisms of action and delivery[J].J Control Release,2013,170(3):365-372.
7 Ibrahim NK,Desai N,Legha S,et al.Phase I and pharmacokinetic study of ABI-007,a Cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel[J].Clin Cancer Res,2002,8(5):1038-1044.
8 Hersh EM,Del Vecchio M,Brown MP,et al.A randomized,controlled phase Ⅲ trial of nab-Paclitaxel versus dacarbazine in chemotherapy-nave patients with metastatic melanoma[J].Ann Oncol,2015,26(11):2267-2274.
9 Tomi＇c K,Tica Sedlar I,Beri＇c Jozi＇c G,et al.Complete response of metaststic melanoma to second line chemotherapy with paclitaxel and carboplatin[J].Acta Med Acad,2018,47(1):82-87.
10 Lee CK,Jung M,Choi HJ,et al.Results of a phase Ⅱ study to evaluate the efficacy of docetaxel and carboplatin in metastatic malignant melanoma patients who failed first-line therapy containing dacarbazine[J].Cancer Res Treat,2015,47(4):781-789.
11 Kottschade LA,Suman VJ,Amatruda T,et al.A phase II trial of nab-paclitaxel(ABI-007)and carboplatin in patients with unresectable stage IV melanoma:a North Central Cancer Treatment Group Study,N057E(1)[J].Cancer,2011,117(8):1704-1710.
12 Guo YQ,Ding Y,Li DD,et al.Efficacy and safety of nab-paclitaxel combined with carboplatin in chinese patients with melanoma[J].Med Oncol,2015,32(9):234.
13 Dalgleish AG.Rational for combining immunotherapy with chemotherapy[J].Immunotherapy,2015,7(3):309-316.
14 Buzaid AC.Biochemotherapy for advanced melanoma[J].Crit Rev Oncol Hematol,2002,44(1):103-108.
15 Eton O,Legha SS,Bedikian AY,et al.Sequential biochemotherapy versus chemotherapy for metastatic melanoma:results from a phase III randomized trial[J].J Clin Oncol,2002,20(8):2045-2052.
16 Atkins MB,Hsu J,Lee S,et al.Phase III trial comparing concurrent biochemotherapy with cisplatin,vinblastine,dacarbazine,interleukin-2,and interferon alfa-2b with cisplatin,vinblastine,and dacarbazine alone in patients with metastatic malignant melanoma(E3695):a trial coordinated by the Eastern Cooperative Oncology Group[J].J Clin Oncol,2008,26(35):5748-5754.
17 Flaherty LE,Othus M,Atkins MB,et al.Southwest Oncology Group S0008:a phase III trial of high-dose interferon Alfa-2b versus cisplatin,vinblastine,and dacarbazine,plus interleukin-2 and interferon in patients with high-risk melanoma-an intergroup study of cancer and leukemia Group B,Children's Oncology Group,Eastern Cooperative Oncology Group,and Southwest Oncology Group[J].J Clin Oncol,2014,32(33):3771-3778.
18 Alrwas A,Papadopoulos NE,Cain S,et al.Phase I trial of biochemotherapy with cisplatin,temozolomide,and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma[J].Melanoma Res,2014,24(4):342-348.
19 Robert C,Schachter J,Long GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med,2015,372(26):2521-2532.
20 Robert C,Thomas L,Bondarenko I,et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J].N Engl J Med,2011,364(26):2517-2526.
21 Patel SP,Kim DW,Bassett RL,et al.A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma[J].Cancer Immunol immunother,2017,66(10):1359-1366.
22 Maio M,Grob J,Aamdal S,et al.Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial[J].J Clin Oncol,2015,33(10):1191-1196.
23 Yamazaki N,Uhara H,Fukushima S,et al.Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated,unresectable or metastatic melanoma[J].Cancer Chemother Pharmacol,2015,76(5):969-975.
24 Funazumi M,Namiki T,Arima Y,et al.Increased infiltration of CD8⁺T cells by dacarbazine in a patient with mucosal penile melanoma refractory to nivolumab[J].Ann Dermatol,2016,28(4):486-490.
25 Kim KB,Sosman JA,Fruehauf JP,et al.BEAM:a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma[J].J Clin Oncol,2012,30(1):34-41.
26 Von Moos R,Seifert B,Simcock M,et al.First-line temozolomide combined with bevacizumab in metastatic melanoma:a multicentre phase II trial(SAKK 50/07)[J].Ann Oncol,2012,23(2):531-536.
27 Ferrucci PF,Minchella I,Mosconi M,et al.Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma[J].Melanoma Res,2015,25(3):239-245.
28 Cui C,Mao L,Chi Z,et al.A phase II,randomized,double-blind,placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J].Mol Ther,2013,21(7):1456-1463.
29 Flaherty KT,Puzanov I,Kim KB,et al.Inhibition of mutated,activated BRAF in metastatic melanoma[J].N Engl J Med,2010,363(9):809-819.
30 Si L,Kong Y,Xu X,et al.Prevalence of BRAF V600E mutation in Chinese melanoma patients:large scale analysis of BRAF and NRAS mutations in a 432-case cohort[J].Eur J Cancer,2012,48(1):94-100.
31 Robert C,Dummer R,Gutzmer R,et al.Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma:a phase 2 double-blind randomised study[J].Lancet Oncol,2013,14(8):733-740.
32 Queirolo P,Spagnolo F,Picasso V,et al.Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib[J].Oncotarget,2016,9(15):12408-12417.
33 Rangwala R,Leone R,Chang YC,et al.Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma[J].Autophagy,2014,10(8):1369-1379.
34 Xia C,Leon-Ferre R,Laux D,et al.Treatment of resistant metastatic melanoma using sequential epigenetic therapy(decitabine and panobinostat)combined with chemotherapy(temozolomide)[J].Cancer Chemother Pharmacol,2014,74(4):691-697.
35 Hong DS,Kurzrock R,Falchook GS,et al.Phase 1b study of lenvatinib(E7080)in combination with temozolomide for treatment of advanced melanoma[J].Oncotarget,2015,6(40):43127-43134.
36 Fukuda K,Funakoshi T,Sakurai T,et al.Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma[J].Melanoma Res,2017,27(4):326-334.
37 Dronca RS,Allred JB,Perez DG,et al.Phase II study of temozolomide(TMZ)and everolimus(RAD001)therapy for metastatic melanoma[J].Am J Clin Oncol,2014,37(4):369-376.
38 Middleton MR,Friedlander P,Hamid O,et al.Randomized phase II study evaluating veliparib(ABT-888)with temozolomide in patients with metastatic melanoma[J].Ann Oncol,2015,26(10):2173-2179.
39 Carvajal RD,Wong MK,Thompson JA,et al.A phase 2 randomised study of ramucirumab(IMC-1121B)with or without dacarbazine in patients with metastatic melanoma[J].Eur J Cancer,2014,50(12):2099-2107.
40 Bedikian AY,Garbe C,Conry R,et al.Dacarbazine with or without oblimersen(a Bcl-2 antisense oligonucleotide)in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase[J].Melanoma Res,2014,24(3):237-243.

[1]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[2]	梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.
[3]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[4]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[5]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[6]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[7]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[8]	杨文娟, 余静, 黄朝, 张俊红, 谢丛华. 化疗早期重度粒细胞下降与小细胞肺癌预后相关性分析[J]. 实用肿瘤学杂志, 2018, 32(1): 19-24.
[9]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[10]	梁语丝, 谭永刚, 邹华伟审校. 低剂量化疗作用机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 538-542.
[11]	石峰,于雁. 节拍化疗通过影响血管形成及免疫系统抑制肿瘤细胞生长的机制[J]. 实用肿瘤学杂志, 2017, 31(4): 316-320.
[12]	董峰, 马君俊, 蔡正昊, 赵轩, 郑民华. 血清miR-21和miR-34a与晚期胃癌患者Folfox化疗方案化疗疗效的关系研究[J]. 实用肿瘤学杂志, 2017, 31(2): 147-151.
[13]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[14]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[15]	孙大为，雷明辉. 高压氧联合术后辅助化疗对口腔癌患者免疫及肿瘤复发的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 533-537.

恶性黑色素瘤化疗研究进展

Progress in chemotherapy for malignant melanoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价